Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Pharmaceutical Research and Manufacturers of America
Pharmaceutical Research and Manufacturers of America
Activities:
Media
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Fasenra for EGPA: addressing unmet needs
Benralizumab could offer patients with EGPA more treatment options, while reducing dependency on oral corticosteroids
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
Bristol Myers Squibb and Cellares partner to expand CAR-T manufacturing capabilities
Cellares will optimise and automate select Bristol Myers Squibb CAR-T cell therapies onto its high-throughput manufacturing program, the Cell Shuttle
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Regulatory
PhRMA board talk with President Trump
PhRMA CEO has issued a statement following his meeting with President Trump regarding the US biopharmaceutical industry
Research & Development
PhRMA member companies invested US$58.8bn in R&D in 2015
Biopharmaceutical industry continues to be most R&D-intensive industry in US economy
You need to be a subscriber to read this article.
Click here
to find out more.
Finance
TPP agreement – a bitter pill to swallow?
US negotiatiors have had to make concessions over biologics protection to secure a Trans-Pacific Partnership (TPP) deal, but health campaigners are unimpressed
Research & Development
PhRMA reports 836 medicines and vaccines in development to treat cancer
Building on decades of progress in the fight against the disease, a robust pipeline of potential new treatments sustains hope for patients and their families
Regulatory
US pharma associations clash over Trans-Pacific Partnership (TPP)
After President Obama secures trade promotion authority powers
Regulatory
Sanofi to expand access to clinical trial data
In support of PhRMA and EFPIA principles on responsible sharing of data
Finance
PhRMA sounds alarm over US budget cuts
Criticises proposal on generics
Subscribe now